KRAS: From undruggable to a druggable Cancer Target

Cited by (273)

Items 201–273 of 273

1. Advances and Challenges in Targeted Therapy for Colorectal Cancer: A Focus on Adenomatous Polyposis Coli and Kirsten Rat Sarcoma Virus Mutations
   Rui‐Hong Gong, Sibao Chen, Guoqing Chen · 2024 · Journal of Translational Gastroenterology
2. Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
   Phaedra C. Ghazi, Kayla T. O’Toole, Sanjana Srinivas Boggaram, Michael T. Scherzer, Mark R. Silvis, Yun Zhang, Madhumita Jagannathan‐Bogdan, Bryan D. Smith, Guillermina Lozano, Daniel Lee Flynn et al. · 2024 · eLife
3. PLK1 and its role in the evolving landscape of KRAS-mutated colorectal cancer
   Harry Myles Harvey, Eric Xueyu Chen · 2024 · Journal of Gastrointestinal Oncology
4. Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models
   Peng, Shengbin, Zhang, Youyan, Lin, Xi, Si, Chong, Van Horn, Robert Daniel, Dempsey, Jack A., Goetz, Eva, Evans, Robert J., Farber, Andrew, Vandekopple, Matthew J. et al. · 2026 · Nature Communications
5. Biophysical and Biochemical Characterization of Structurally Diverse Small Molecule Hits for KRAS Inhibition
   Cynthia V. Pagba, Amit Kumar Gupta, K. M. Dilsha, Parisa Sadrpour, Jacob L. Jakubec, Priyanka Prakash, Dharini van der Hoeven, Kwang‐Jin Cho, Scott R. Gilbertson, Alemayehu Abebe Gorfe · 2024 · ChemBioChem
6. VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small Cell Lung Cancer
   Xuechao Yang, Shu Zhang, Yang Yang, Xiaoqun Duan, Xiaochuan Li · 2024 · Technology in Cancer Research & Treatment
7. ETS1 Promotes Aerobic Glycolysis and Growth in Head and Neck Squamous Cell Carcinoma by Targeting RRAS2
   Jianguo Liu, Zhi Wang, Xiaoyan Tian, Bingbin Xie, Ke Liu · 2024 · Biochemical Genetics
8. Targeting MET and KRAS G12C co-occurring mutation in metastatic adenoid cystic carcinoma of the trachea: a case report
   Ling Zhang, Tonghui Wang, Yan Xu, Youxin Ji, Keke Nie · 2025 · Journal of Medical Case Reports
9. Restoration of chemosensitivity to drug resistant breast cancer cells through peptide activation of the anaphase promoting complex
   Cordell A. VanGenderen, R. E. Harris, G. Mercier, S. Valentine, Mathew Lubachowski, C. Su, G.F. Davies, T. G. Arnason, Troy Anthony Alan Harkness · 2026 · Scientific Reports
10. Multi-modal characteristics of LncRNA-derived subtypes in colorectal cancer
    Minghao Xiong, Jie Li, Xue Li, Jiaojiao Zhao, Qin Liu, Mengjie Tu, Fanxin Zeng · 2025 · BMC Medical Genomics
11. Optimization of α-Fluoro, β-Heteroaryl Acrylamide Warheads for KRAS G12C Active-State Inhibition
    Matthew L. Condakes, Rita L. Civiello, Brian L. Venables, Derek B. Danahy, Richard R. Moore, Srividya B. Balachander, Lisa Sinang Chourb, Daniel P. Downes, Dieter M. Drexler, Liudmila Dzhekieva et al. · 2026 · Journal of Medicinal Chemistry
12. A Tasquinomod-loaded dopamine-modified pH sensitive hydrogel is effective at inhibiting the proliferation of KRAS mutant lung cancer cells
    Jun Xu, Chuxi Zhang, Chun Cheng, Jun Yang, Chenxi Li, Xia Liu, Yi Sang · 2022 · Journal of Applied Biomaterials & Functional Materials
13. Personalized Systemic Cancer Therapy
    Kevin B. Kim, Mohammed Kashani–Sabet · 2022 · Springer eBooks
14. KIAA0101 and IL2RA Were Identified as Core Genes in Hormone-Resistant Nephropathy
    Ying Chen, Shuyi Qian, Yinyin Chen, Kanghan Liu, Wei Yin, Xun Luo · 2022 · Disease Markers
15. A Novel NRAS Variant Near the Splice Junction in Moroccan Childhood Acute Lymphoblastic Leukemia: A Molecular Dynamics Study
    Hanaa Skhoun, Meriem El Fessikh, Mohammed Khattab, Basma Mchich, Aomar Agadr, Rachid Abilkassem, Nadia Dakka, Delphine Flatters, Anne‐Claude Camproux, Zohra Ouzzif et al. · 2024 · Biochemical Genetics
16. SPAG6 Promotes Multiple Myeloma Through Activation of the MAPK/ERK Signaling Pathway
    Junnan Li, Xinyu Yan, Li Ding, Jiaxiu Yin, Ping Li, Lin Liu · 2025 · Frontiers in Pharmacology
17. Covalent Bifunctional Molecules (CBMs): Achievements and Challenges
    Yuting Xin, Fangsu Chen, Qidong You, Lei Wang, Qiuyue Zhang · 2025 · Medicinal Research Reviews
18. Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations
    Johannes Schöche, Dora Niedersüß‐Beke · 2022 · memo - Magazine of European Medical Oncology
19. The translational role of SOS1 in colorectal cancer
    Diego Alem, Xinrui Yang, Francisca Beato, Bhaswati Sarcar, Alexandra F. Tassielli, Ruifan Dai, Tara L. Hogenson, Margaret A. Park, Kun Jiang, Jianfeng Cai et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
20. PAMR1 is a favorable diagnostic and prognostic biomarker in hepatocellular carcinoma
    Xiaoping Zhou, Teng Liu, Shihua Deng, Ting Zhang, Dongming Wu, Ying Xin Xu · 2022 · Research Square
21. Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
    Phaedra C. Ghazi, Kayla T. O’Toole, Sanjana Srinivas Boggaram, Michael T. Scherzer, Mark R. Silvis, Yun Zhang, Madhumita Jagannathan‐Bogdan, Bryan D. Smith, Guillermina Lozano, Daniel Lee Flynn et al. · 2024 · eLife
22. Potential Roles of Long Non-Coding RNAs in Regulating Cell Proliferation, Invasion, and Metastasis in Ovarian Serous Cystadenocarcinoma
    Mujie Kan, Housen Zhang, Chengya Dong, Tianmin Xu, Qi Li · 2021 · Research Square
23. After Decades, RAS Mutation has Finally Become a Therapeutic Target
    Nabih Naim, Sara Moukheiber, Karim Jaber, Hampig Raphaël Kourié · 2021 · Personalized Medicine
24. Genetic and genomic medicine relevance to cancer prevention, diagnosis, and treatment
    Moyra Smith · 2021 · Elsevier eBooks
25. Pan-Cancer Analysis of Kinesin Family Member 2C (KIF2C) in Human Tumors
    Bixi Zhang, Yanchun Li, Siming Gong, Yingjuan Duan, Meihua Xu, Canxia Xu, Hao Wu · 2022 · Research Square
26. Potential Roles of Long Non-coding RNAs in Regulating Cell Proliferation, Invasion, and Metastasis in Ovarian Serous Cystadenocarcinoma
    Mujie Kan, Housen Zhang, Chengya Dong, Tianmin Xu, Qi Li · 2021 · Research Square
27. Recent Developments, Challenges and Opportunities in Targeting the KRAS Pathway
    Manoj Kumar Pothuganti, Sayan Mitra, Pravin S. Iyer, Nagaraj M. Gowda · 2022 · Letters in Drug Design & Discovery
28. The Somatic Mutational Landscape and Role of ARID1A Gene in Hepatocellular Carcinoma
    Guang-Xiao Meng, Chuncheng Yang, Lun‐Jie Yan, Yafei Yang, Yu-Chuang Yan, Jian‐Guo Hong, Zhiqiang Chen, Zhao‐Ru Dong, Tao Li · 2022 · SSRN Electronic Journal
29. Bioinformatics Analysis of Kinesin Family Member 2C in Human Tumors: Novel Prognostic Biomarker and Tumor Microenvironment Regulator
    Bixi Zhang, Yanchun Li, Xiaoyang Pang, Hao Wu · 2022 · Research Square
30. Identification of Covalent Ligands – from Single Targets to Whole Proteome
    Chau Ngo, Arunika I. Ekanayake, Chao Zhang · 2023 · Israel Journal of Chemistry
31. Data from Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma
    Youpei Lin, Lihua Peng, Liangqing Dong, Dongbing Liu, Jiaqiang Ma, Jian Lin, Xiaofang Chen, Penghui Lin, Guohe Song, Mao Zhang et al. · 2023
32. Supplementary Table from Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma
    Youpei Lin, Lihua Peng, Liangqing Dong, Dongbing Liu, Jiaqiang Ma, Jian Lin, Xiaofang Chen, Penghui Lin, Guohe Song, Mao Zhang et al. · 2023
33. Supplementary Table from Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma
    Youpei Lin, Lihua Peng, Liangqing Dong, Dongbing Liu, Jiaqiang Ma, Jian Lin, Xiaofang Chen, Penghui Lin, Guohe Song, Mao Zhang et al. · 2023
34. Targeting Immune Determinants of Creating Tumor Heterogeneity in Lung Cancer
    Chie Kudo‐Saito, Tomonari Kinoshita · 2023 · Interdisciplinary cancer research
35. Identification and Analysis of Anticancer Therapeutic Targets from the Polysaccharides PSK and PSP Using Inverse Docking
    Carlos Iván Lopéz-Gil, Alejandro Téllez‐Jurado, Marco Antonio Velasco-Velázquez, Miguel Ángel Anducho-Reyes · 2023 · SSRN Electronic Journal
36. A Review of the in Silico Design and Development Approaches of Ras-Specific Anticancer Therapeutics
    Parinaz Motiei, Hamid Reza Heidari, Mohammad Saeid Hejazi, Ommoleila Molavi, Elnaz Mehdizadeh Aghdam · 2023 · International Journal of Peptide Research and Therapeutics
37. A Suite of Biochemical and Cell-Based Assays for the Characterization of KRAS Inhibitors and Degraders
    Medhanie Kidane, Rene M. Hoffman, Jennifer K. Wolfe-Demarco, Ting-Yu Huang, Chi-Ling Teng, Luis M. Gonzalez Lira, Jennifer Lin‐Jones, Gabriel Pallares, Jane E. Lamerdin, Nicole B. Servant et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
38. eLife Assessment: Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
    Rachel Evans · 2024 · eLife
39. Reviewer #2 (Public Review): Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
    2024 · eLife
40. Author response: Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
    Phaedra C. Ghazi, Kayla T. O’Toole, Sanjana Srinivas Boggaram, Michael T. Scherzer, Mark R. Silvis, Yun Zhang, Madhumita Jagannathan‐Bogdan, Bryan D. Smith, Guillermina Lozano, Daniel Lee Flynn et al. · 2024 · eLife
41. An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer
    Christiana Mo, Bhawneet Chadha, Chaoyuan Kuang · 2024 · Clinical Colorectal Cancer
42. Conclusions: the future of RAS drug discovery
    Adrian L. Gill, Kevan M. Shokat · 2024 · Elsevier eBooks
43. Influence of recipient KRAS gene rs712 polymorphisms on the overall survival rate of hepatocellular carcinoma after hepatic transplantation
    Tiancheng Chu, Rulin Zhang, Xiaolei Liu, Lin Li, Yanning Li, Ziguang Niu, Heng Quan, Yingying Zhao, Yaohua Li · 2024 · Clinical and Experimental Medicine
44. Antagonistic interaction between miR-143 and KRAS gene regulating male mouse germ cell apoptosis
    Lu Yu, Shudong Niu, Guisheng Zhang, Yanfeng Guo, Baotong Fu, Miaomiao Wang, Jianan Liu, Haili Zhang, Wen Lu, Ming Zhang · 2025 · Theriogenology
45. An updated patent review of antitumor macrocyclic kinase inhibitors (2019 present)
    Xintao He, Lu Chen, Shuangshuang Wu, Zhichao Chen, Wufu Zhu, Dan Qiao · 2025 · Expert Opinion on Therapeutic Patents
46. Mechanism of Action and Research Progress of Drugs Targeting KRAS G12-Mutant Tumors
    金蓉 郑 · 2025 · World Journal of Cancer Research
47. Detection of postoperative recurrence in colorectal cancer: Exploring the value of liquid biopsy
    В. В. Костюченко, Ihor O. Vynnychenko, Yuliia Moskalenko, V. Pohorila · 2025 · Regulatory Mechanisms in Biosystems
48. A prognostic signature for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
    Yincheng Liu, Ningyi Xue, Feidie Duan, Kunli Zhao, Yan Liang, Jing Zhao, Lei Zhang, Yancheng Xu, Yuzi Zhang, Guoqiang Wang et al. · 2025 · Scientific Reports
49. Evolutionary Dynamics of Oncosuppression Under Selection Pressure
    M. Potievskiy, P. Shatalov, I. Klabukov, D. Atiakshin, A. Yakimova, D. Baranovskii, P. Shegai, Andrey Kaprin · 2025 · Life
50. A Hybrid In Silico Approach for Identifying Dual VEGFR/RAS Inhibitors as Potential Anticancer and Anti-Angiogenic Agents
    Alessia Bono, Gabriele La Monica, Federica Alamia, Dennis Tocco, Antonino Lauria, Annamaria Martorana · 2025 · Pharmaceuticals
51. Clinical Progress of Targeted KRAS Drugs Combined with Immune Checkpoint Inhibitors in the Treatment of Pancreatic Cancer
    Lu Wang · 2025 · Transactions on Materials Biotechnology and Life Sciences
52. FragmentScope - exploring the fragment space with learned surface representations
    Evgenia Elizarova, Irina Morozova, Ilia Igashov, Olivia Gampp, David Robin Pavel Iosub, Arne Schneuing, Kelvin Lau, Davide M. Ferraris, Florence Pojer, Roland Riek et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
53. Additional file 1 of Molecular and phenotypic spectrum of cardio-facio-cutaneous syndrome in Chinese patients
    Feng, Biyun, Li, Xin, Zhang, Qianwen, Yirou Wang, Shili Gu, Yao, Ru-en, Li, Zhiying, Shiyang Gao, Chang, Guoying, Li, Qun et al. · 2024 · Figshare
54. Single-cell omics in investigating the effect of CAFs with KRAS overexpression on the malignant progression of anaplastic thyroid cancer
    Haohang Sun, Qi Chen, Guo‐Qing Li, Mengze Chen, Ji Dai, Meidi Yan · 2026 · Journal of the Chinese Medical Association
55. Farnesyltransferase inhibitor LB42708 disables oncogenic RAS signaling and overcomes gefitinib resistance in NSCLC via FTase α-subunit and RAS degradation
    Guancong Luo, Dexuan Li, Jun Peng, Rongsheng Liu, Yajing Meng, Richard Ward, Yangyang Zhang, Xinyu Zhang, Fengxian Cui, Jiwei Wang et al. · 2026 · Cell Communication and Signaling
56. Colorectal Micropapillary Adenocarcinoma: Molecular Mechanisms and Clinical Implications
    Baijian Chen, Runqi Zhang, Yihan Ding, Kai Zhang, Xiaohang Song, Jingsong Chen · 2026 · Journal of Gastrointestinal Cancer
57. KRAS Gene Variants rs712 and rs61764370 as Predictive Markers of Breast Cancer Susceptibility in a Bangladeshi Population: A Case‐Control Study
    Taslia Afrose Eva, Mst. Mahfuja Tabassum Miti, Nusrat Zahan Nisha, Zarin Tasnim, Tithi Saha, Mayesha Khan, Nafisa Tabassum Moon, Md. Aminul Haque · 2026 · Health Science Reports
58. TARDBP Mediates the MAP 3 K 11/ SLC 3 A 2/ GPX 4 Axis in Alzheimer's Disease Rats by Enhancing KRAS m RNA Stability
    QiTao Zhao, Yadong Yu, FuJiang Wang, Ya Wang, Peng Shao, LianDong Zhao · 2026 · Journal of Cellular and Molecular Medicine
59. Flavonoids as Modulators of Cancer Cell Signaling Pathways: PI3K/Akt, MAPK, and NF-κB
    Muhammad Bello Usman · 2026 · Springer eBooks
60. Synthesis and Biochemical Characterization of Investigational Pyrazolopyrimidine-Based Allosteric KRAS Modulators
    Cynthia V. Pagba, K. M. Dilsha, Rakshya Ojha, Jacob L. Jakubec, Xiaowen Liang, Abraham C. Sianoya, Paul Mark B. Medina, Scott R. Gilbertson, Alemayehu Abebe Gorfe · 2026 · ACS Medicinal Chemistry Letters
61. Application of small interfering RNAs and drug combination for pancreatic cancer therapy
    Chaoyang Zeng, Shuzhen Chen · 2026 · Journal of drug targeting
62. Evolution and breakthroughs of RAS-targeted therapy: A narrative review
    Chinmoy Kr. Bose · 2026 · Cancer Research Statistics and Treatment
63. KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis
    Yici Yan, Leyi Zheng, Hongfei Wang, Leitao Sun, Xing Xu · 2026 · Frontiers in Immunology
64. Discovery of a Potent and Selective KRAS G12D Degrader based on PROTAC Degradation
    Lili Jiang, Wenyan Yang, Yanqing Liu, Gangjian Li, Xiaomin Luo, Yubo Zhou, Jiangjiang Qin, Youlu Pan, Wenhai Huang · 2026 · European Journal of Pharmaceutical Sciences
65. In-silico study to identify a potential KRAS G12D targeting compound using MRTX1133 as the lead molecule
    Aparana K, C Guruswaroop, Kavya K M, Devaiah N J, Sannathammegowda Krishnaveni · 2026 · In Silico Research in Biomedicine
66. Survivin Promotes the Formation of a Microtubule-Based Glycolytic Hub
    Jacob Neumann, Wen-Hsuan Chang, Sarah E. Ackermann, Matthew R. Zanotelli, Tomer Markovich, 杨闰英, Jolie R. Lefkowitz, Shun Enomoto, Henry H. Le, Min-Ting Lee et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
67. Targeting KRAS reprograms a Treg-dominant immunosuppressive microenvironment and sensitizes KRAS-mutant gastric adenocarcinoma to CTLA-4 immunotherapy
    Xiaohuan Tang, Peiyao Yang, Xiaoyong Guo, Shuhua Wei, Xiaojing Cheng, Mengyuan Li, Yigang Bao, Sachiyo Nomura, Yu Sun, Longtao Huangfu et al. · 2026 · Science China Life Sciences
68. Discovery of Novel Oral Covalent Inhibitors Targeting Active GTP-Bound KRASG12C with Potent Antitumor Activity
    Juan del Pozo, Elisabeth T. Hennessy, Patrick Schoepf, Kazuaki SHIBATA, Kei Akemoto, Naomi Abe, Christopher Agnew, Hiroki Asakura, David Jonathan Bennett, Samantha A. Burgess et al. · 2026 · Journal of Medicinal Chemistry
69. BindingDB Entry 50019814: Annual review of KRAS inhibitors in 2022.
    BindingDB · 2024 · UC San Diego
70. BindingDB Entry 50021330: Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.
    BindingDB · 2025 · UC San Diego
71. BindingDB Entry 50021056: Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity.
    BindingDB · 2025 · UC San Diego
72. BindingDB Entry 50017595: Efficient targeted oncogenic KRAS
    BindingDB · 2023 · UC San Diego
73. BindingDB Entry 50021455: A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor.
    BindingDB · 2025 · UC San Diego